’5 dr life habeebullah sciences · 2018. 11. 14. · requirements) regulations, 2015 ref:...

’5 Dr Habeebullaha Life Sciences

T0: Date: 12/11/2018

1) BSE timited

PJ. Towers, Dalal Street,

Mumbai — 400 001

2) Metropolitan Stock Exchange of India Limited

Vibgyor Towers, 4fn floor, Plot No C 62, Opp‘ Trident Hotel,

Sandra Kurla Complex, Sandra (E), Mumbai — 400 098

3) Ahmedabad Stock Exchange Limited

Kamdhenu Complex, Oppl Sahajanand College,

Panjara Pole, Ambawadi. Ahmedabad - 380 015

u

Sub: Outcome of Board Meeting under Regulation 30 81 33 of SEBI (Listing Obligations and Disclosure

Requirements) Regulations, 2015

Ref: Company’s Letter dated Wednesday, 31“ October, 2018

We wish to inform you that the Board of Directors of the Company. at its meeting held today i.e., Monday,

12".1 November, 2018 at Registered Office, have considered and approved inter-alia, the following

1. Standalone UnAAudited Financial Results for Quarter 11 and Half Year Ended 30‘h September, 2018

2. Statement of Assets and Liabilities for Half Year Ended 30‘h September, 2018

3. Limited Review Report for Quarter 11 and Half Year Ended 30th September, 2018 issued by

M/s. MSKA & Associates, Statutory Auditors of the Company.

The meeting commenced at 3.00 PM and concluded at 4.00 PM.

Request you take the same on records,

Thanking you‘

For DR HABEEBULLAH LIFE SCIENCES LIMITED

7:?“K. Krishnam Raju

Encl: as above

Regd.()fi 2

Corp Off : Ni

Dr Habeebullah Life Sciences Ltd(Formerly Known as PC Products India Limited)

5-36/1?th Dil, Chintalmet X Roads, Upperpally. Rajet‘idra Nagar Mandel, l'lyderabad , 500048l 'l‘S.lndia

0.] Phase I. Vasudcva‘s Bloomfield Elation. Khajaguda, Nanakramgudm Hyderabad - 50000818, India

CIN No. : L851]0TGI996PLC099198 Email : inibl’adrhlslxom, pcpmductsindial’ciagmaiLComContact No.: 040 ~ 2970 3333. +91 9030057370 Website : wwwdrhlslcom

|||>

‘lli

Life Sciences

PAR“ ) Rs in lekns

SFANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER il AND HALF VEAR ENDED 30m SEPTEMBER, 2013

Particulars QUARTER ENDED Half Year ended' '

Yearended 31

3 Months corresponding 3 Preceeding 3 Half year ended Half year ended 03-2018

ended months ended in morm‘is ended 30—09-2018 3009-2017S'Na

30—09-2018 previous year 30-05—2018

3009-2017

UnAud‘rted anAndited UnAudited unAudited UnAudited Audited

1 Revenue from Operations 52.92 14.95 30.45 03.30 17.50 61.67

li other income— - 1 . » -

iii Total Revenue (M!) 52.92 14.95 30.46 33.30 17.50 61.67

lV Expenses

Cost of Material Consumed 4.95 0.50 3.11 3.07 0.56 6.41

Purchase ofSiocka'nrtrade .. .

- — -

Changes in inventories of finished goods, Work in - - - - - -

Droizress and Stock in trade- » - . ~ -

Employee benefits expense 31.29 17.02 34.37 65.66 40.01 37.42

Finance Costs. . .

—.

Depreciation and Amanisatipn expense 0.09 . 0.09 0.15 — 0.23

Professional Charges 14.43 . 10.81 25.24 .

Other Expenses 50.717 6.287 44.85 105.55

7 17.45 7 7

53.77

Total Expenses 11.1.45 24.66 93.23 204.71 53.02 155.02

v Pruitt/(mas) from before Exceptional items and tax

((.iv) (55.55) (9.71) (52.77) (12133) (40.52) (102.15)

Vl Exceptional Items. - - —

.

Vii Profit/(toss) before m (v40) (58.50) (9.71) (51.77) (12133) (40.52) (102.15)

vm Tax Expense:- . - - - -

Current Tax

'

. » - . - -

Deferred Tax- - - . . .

IX Profit] (Loss) for the period from Continuing

operations (Vii-Vila) (53.55) (9.71) (62.77) (121.33) (40.52) (102.15)

)1 Profit] (Loss) from discontinuing operations . . . . . .

Xi Tax Expense of discontinuing operations . . _ . . .

Xil Profit] (Loss) for the period from discontinuing

operations after tax (X-Xl) . . . _ . _

XI" Pmfit/ (LOSS) for Ihe periad (lX+XII) [53.56) (9.71) (62.77) (121.33) (40.52) (102.15)

Xi'v‘ other Comprehensive income

A) (i) items that will not he reclassified to profit or

loss

(ii) Income Tax related to items that will not be

relciassified to profit or 1055 B)

(i) items that will be reciassiied to profit or ioss

(ii) Income Tax relating to items that will be

re£i§5€i gd to nmfrr or In“1 - . e . .

XV Total Comprehensive income for the periad

(xiilexw) (Comprising Pmfit (loss) and Other

Comprehensive Income for the Period) (58.56) (9.71) (62.77) (12133) (40.52) (102.15]

XVI Earnings Per Equity snare Ire: Continuing

Operations) (Face Value imt 10/- each)

2) Basic (0.49) (0.09) (0.53) (1.02) (0.40) (0.96)

z) Diluted (0.40) (0.09) (0.45) (0.04) (0.40) (0.74)

XVII Earnings Per Equity Share (For Discontinued

Operations) (Face Value NR 10/- each)

1) Basie

2) Diluted

xvm Earnings Per Equity Share (Formminued and

Discontinued 0perations)(Face Value [NR 10/.

each) 1)

Basic (0.49) (0.09) (0.53) (0.98) (0.40) (0.95)

2) Diluted (0.40) (0.09) (0.45) (001) (0.40) (0.74)

Xix Paid Up Equity Share Capital (Face Value arm 10/

per share) 1,221.37 1025.37 1,221.37 1,221.37 1025.37 1175.07

XX Raerves excluding Revaluation memes

as per balance sheet of previous

W (142.23) (190.07) (142.23) (142.23) (190.07) (142.23)


chd.()fi' : 2—5—36/(‘LRD/1. Chlnlulmcl X Roads. Upperpaiiy, Rajendl'a Nagal' Manda]. Hyderabad - 500043. TSJndia

Corp 011' 0.1 1. Pilzise i. \/'asud0\ 0’s Bioomfield Elation. Khajaguda. Nanakmmgudu. Hyderabad — SOOOUETS. India

CIN N). : 1.85 i HiTGi‘WéPLCOQQiQS Email : iniblk2;(il'llisl.00ili. pcprodilctsilidialiirgmai1.00m(30111001 N0; 040 - 2970 3333, +91 9030057370 Website : wwsi‘xirh151.com

Dr Habeebuflah

"é; Dr Habeebullahé Life Saences

Notes:

1 The Unaudited Standalone finanaal results for the Quarter Ii and period ended 30, September 2013 were reviewed and recommended by the Audit Committee

and approved by the Board of Directors at its meeting held on November 12, 2013. The Statutory Auditors have otrried out the Limited Review ofthe

Unaudited Standalone financial Results in accordance with Regulation 33 of SEEI lLODR) Regulations, 2015).2 The Unaudited standalone financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in

Indian Accounting Standards {IND ASl 34 interim Financial Reporting proscribed under section 133 ufthe Companies Act, 2013 ("the Act“) read wnh relevant

rules issued thereunder, other accounting principles generally aocepted in india and guidelines issued by Securities and Exchange Board oi lndia(“SEBl"l and

Regulation 33 of 5551 (max) Regulations, 2015 am: sEal Circular dated 05th July, 2016.

3 Adoption of ind AS 115 . Revenue from contracts with customers

Effective April 1, 2018, the Company has adopted lnd AS 115 ”Revenue from Contracts with Customers” using the cumulative catchrup transition method

which is applied to contracts that were nut completed as of April 1, 2018. Accordingly, the comparatives have nut been retrospectively adjusted. The effect an

adoption of Ind AS 135 was insignificant on thefiiiancial statements.

4 The Company has only one reportable segment as per requirements of AS 108 "Operating Segments" Le, Health Care Sector Hence, the separate disclosure on

Segment information is not required.

The figures of the corresponding prevlous period have been regrouped/reclassified wherever necessary, to make them comparable.

6 The results are also available an the webiste of the Company wwfirhlslxom

Place : Hyderabad For DR HABEEBULIAH LIFE SGENEES LIMITED

Bate 2 11/11/2018

K. Krishnam RajuExecutive Chairman (DIN 00814659)


chd.0fi' : 2-5—36J‘CLRD/l. Chilltalmel X Roads. Upperpally, Rajendra Nagal’ Mandal. Hyderabad a 500048a TS.Indla

Corp 00" : No.11, Phase I, Vasudcva’s Bloomfield Elation. Khajaguda, Nallakramguda, Hyderabad — 500008.TS. India

0. : 1485 l 1 ()TG 1996PLC099198 Email : inlblti2drlllsl.com, pcproductslndialij gmailcomContact [N t.: 040 - 2970 3333, +91 9030057370 Website : wwwdrhlal,cmn

5% or Habeebuflahé Life Saences

Statement of Assets and Liabilities

(INR. in iakhs ]Half Year Ended Year Ended

Particulars 30-09-18 31-03-18

Unaudited Audited

ASSETS

Non Current Assets

Property, Plant and Equipments 3.43 1.99

Capital Work In Progress

Investment Prpoerty

Goodwill

Other lntangable Assets

lntangable Assets under development 153.03 91.66

Biological assets other than bearer plantsFinancial Assets:

Investments 487.06 487.06

Trade Receivables

Loans

Others

Deferred Tax Assets (net)

Other Non Current Assets

Total Non Current Asets 643.53 580.71

Current Assets

Inventories 14.80 9.52

Financial Assets

Investments

Trade Receivables 217.68 287.4

Cash and Cash Equivalents 1.09 33.23

Bank balances other than above 5.86

Loans 96.74 70

Others

Current Tax Assets (net)

Other Current Assets 300.22 241.85

Total Current Assets 636.38 642.00

Total Assets_ 1,279.91 1,222.71

EQUITY AND LIABILITIES

Eguky

Equity Share Capital 1,221.37 1,175.87

Other Equity

Reserves & Surplus (218.05) (142.23)Share warrants 129.75 152.50

Total - Equity 1,133.07 1,186.14


Regd.()ff : 2-5-36/(TLRD/l. Chintalmet X Roaés. Upperpally. Rajendra Nagar Mandel, Hyderabad - 500048. TS.India

Corp Olf : No.1 1. Phase I. Vasudeva’s Bloomfield Elation. Khajaguda. Nanakramguda, Hyderabad ~ SOUOOSTS. India

CIN N0. : L85110TGI996PLCO99198 Email : infoai drhlsl.c0m. pcproductsindlaaggmaiLeomContact New 040 — 2970 3333, +91 9030057370 Website : www.clrhlsleom

E“ or HabeebullahA Life SCiences

Liabilities

Non Current Liabilities

Financial Liabilities

Borrowings 63.00 '

Trade Payables

Other Financial Liabilities

Provisions

Deferred Tax Liabilities (net)

Other Non Current Liabilities

Total Non Current Liabilities 63.00 —

Current Liabilities

Financial Liabilities

Borrowings

Trade Payables 23.44 621

Other Financial Liabilities

Other Current Liabilities 24.11

Provisions 6041 6.25

Currenr Tax Liabilities (net)

Total Current Liabilities 83.84 3657

Total - Equity and Liabilities 1,279.91 1f222.71

Place : Hyderabad For DR HABEEBULLAH LlFE SCHENCES LIME

Date : 12/11/‘2018

K. Krishnam Raiu

Executive Chairman (BlN 00814650)


Rengfi‘ : 2<5~36/CLRD/l, (‘hintalmei X Roads, Upperpally, Rajendra Nagar Mandal. Hyderabad » 500048. TS.lndia

Corp Off : No.1] A Phase L Vasudeva‘s Bloomfield Elation Khajaguda. Nanakramguda, Hyderabad — SOOOORTS. India

CIN N0. : L85 1 l OTG l 996PLC099I98 Email : infoQi‘drhlslpom, poproducisindiaqi‘gmail.comContact N .: 040 ~ 2970 3333, +91 9030057370 Website : wwwdrhlsicom

201 E: 202, Floor 2, Manbhum Jade Towers

M S KA 6~3-1090lAr‘12 & i3, Katriya Hotel Lane

Somajiguoa, Hyderabad 500682, lNDlA

Tel: *9! 40 3024 2999

E? Associates

Chartered Accountants

Limited Review Report

Review Report to

The Board of Directors

DR HABEEBULLAH LIFE SCIENCES LIMITED

1. We have reviewed the accompanying statement of unaudited standalone financial results for the

quarter ended 30m September, 2018 and the year to-date results for the period in April 2018 to 30‘h

September, 2018 and financial position as on 30‘“ September, 2018 (‘the Statement’) of DR

HABEEBULLAH LiFE SCIENCES UMITED ('the Company’), being submitted by the Company pursuant to

the requirements of Regulation 33 as modified by Circular No. ClR/CFDIFAC/ 62/2016 dated July 5,2016 and Regulation 52 as modified by Circular No. CIR/ lMD/ DF1/69/2016 dated August 10, 2016 read

with Regulation 63(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure

Requirements) Regulations, 2015 (Listing Regulations).This Statement, which is the responsibility of the Company's Management and has been approved bythe Board of Directors, has been prepared in accordance with ind AS 34 ‘Interim Financial Reporting',prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunderand other recognized accounting practices and policies generally accepted in lndia. Our responsibility isto issue a report on the Statement based on our review.

2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Reviewof interim Financial lnfonnation Performed by the independent Auditor of the Entity issued by theInstitute of Chartered Accountants of India. This standard requires that we plan and perform thereview to obtain moderate assurance as to whether the Statement is free of material misstatement. Areview is limited primarily to inquiries of Company personnel and analytical procedures applied to

financial data and thus provide less assurance than an audit. We have not performed an audit and

accordingly, we do not express an audit opinion.

3. Based on our review conducted as above, nothing has come to our attention that causes us to believe

that the accompanying Statement of unaudited standalone financial results and financial position whichare prepared in accordance with Ind I6 34, prescribed under Section 133 of the Companies Act, 2013

read with relevant rules issued thereunder and other recognized accounting practices and policies has

not disclosed the information required to be disclosed in terms of the Listing Regulations including themanner in which it is to be disclosed, or that it contains any material misstatement.

For MSKA & Associates (Formerly known as MZSK a Associates)

Ananthakrishnan G WPartner

Membership No.:205226

Place: HyderabadDate: 12‘“ November, 2018

Head office: Floor 3, Enterprise Centre, Nehru Road, Near Domestic Airport, Vile Parle (E), Mumbai 400099, INDIA, Tel: «91 22 3358 9800Sengaiuru l Chennai I Hyderabad l Kolkata l Mumbai 1 New Delhi , Gurugrarn ] Pune mm.mska.in

’5 dr life habeebullah sciences · 2018. 11. 14. · requirements) regulations, 2015 ref:...

Documents